Lin Lu
University of Michigan
13 Papers
40 Citations
Lin Lu is an academic researcher from University of Michigan. The author has contributed to research in topics: Cancer stem cell & Immune system. The author has an hindex of 10, co-authored 13 publications. Previous affiliations of Lin Lu include Sun Yat-sen University.
Chat about Author
Papers
Cancer stem cell vaccine inhibits metastases of primary tumors and induces Humoral immune responses against cancer stem cells
Lin Lu,Huimin Tao,Alfred E. Chang,Yangyang Hu,Guoshun Shu,Quanning Chen,Martin Egenti,John H. Owen,Jeffrey S. Moyer,Mark E. Prince,Shiang Huang,Max S. Wicha,Jian Chuan Xia,Qiao Li +13 more
TL;DR: The data suggest that the CSC-DC vaccine approach may be useful in the adjuvant setting where local and systemic relapse are high after conventional treatment of cancers.
99
IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival.
Lin Lu,Ke Pan,Hai Xia Zheng,Jian Jun Li,Hui Juan Qiu,Jing Jing Zhao,De Sheng Weng,Qiu Zhong Pan,Dan Dan Wang,Shan Shan Jiang,Alfred E. Chang,Qiao Li,Jian Chuan Xia +12 more
TL;DR: With the analyses of 181 ESCC patients, a correlation of higher number of tumor-infiltrating CD1a+ DCs with significantly improved overall survival of patients with ESCC is found.
98
Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10
Huimin Tao,Lin Lu,Lin Lu,Yang Xia,Yang Xia,Fu Dai,Yi Wang,Yangyi Bao,Steven K. Lundy,Fumito Ito,Qin Pan,Xiao-Lian Zhang,Fang Zheng,Guoshun Shu,Bingmu Fang,Jinhong Jiang,Jianchuang Xia,Shiang Huang,Qiao Li,Qiao Li,Alfred E. Chang +20 more
TL;DR: The biological function of antitumor effector B cells, which may offer alternative cellular therapies to cancer, is defined and Trafficking of TDLN B cells in vivo suggested that they were recruited to the tumor and lung as well as secondary lymphoid organs.
96
Therapeutic Efficacy of Cancer Stem Cell Vaccines in the Adjuvant Setting.
Yangyang Hu,Lin Lu,Yang Xia,Xin Chen,Alfred E. Chang,Robert E. Hollingsworth,Elaine M. Hurt,John H. Owen,Jeffrey S. Moyer,Mark E. Prince,Fu Dai,Yangyi Bao,Yi Wang,Joel Whitfield,Jian Chuan Xia,Shiang Huang,Max S. Wicha,Qiao Li +17 more
TL;DR: Overall, the results offered a preclinical proof of concept for the use of ALDH(high) CSC-DC vaccines in the adjuvant setting to more effectively limit local tumor recurrence and spontaneous pulmonary metastasis, as compared with traditional DC vaccines, with increased host survival further accentuated by simultaneous PD-L1 blockade.
Evaluation of the immunogenicity of ALDHhigh human head and neck squamous cell carcinoma cancer stem cells in vitro
Mark E. Prince,Li Zhou,Li Zhou,Jeffrey S. Moyer,Huimin Tao,Huimin Tao,Lin Lu,Lin Lu,John H. Owen,Martin Etigen,Fang Zheng,Fang Zheng,Alfred E. Chang,Jian-Chuan Xia,Gregory T. Wolf,Max S. Wicha,Shiang Huang,Xiubao Ren,Qiao Li +18 more
TL;DR: It is feasible to generate DCs from the PBMCs and isolate ALDH(high) CSCs from cultured tumor cells of the patients with HNSCC to prepare CSC-DC vaccines that can induce anti-HNSCC CSC cellular and humoral immunity, indicating its potential clinical application to treat patients with hNSCC.
25